Featured News

New research from Tampere University in Finland shows exciting progress in a new drug for celiac disease. This drug, ZED1227 could be used alongside a gluten-free diet to help manage celiac disease.  In celiac disease, gluten causes inflammation and damage to the intestines. This happens because gluten attaches to specific proteins in the body called…

The Celiac Disease Foundation is committed to accelerating research aimed at finding potential treatments and cures for celiac disease beyond the gluten-free diet. In order to do this, we need patients like you to participate in clinical trials. Clinical trials are necessary to determine if new treatments are safe and effective. Your involvement not only advances scientific…

A new international study published in the journal Gastroenterology sheds light on the extensive economic burden of celiac disease. In addition to the cost of gluten-free  foods, the authors address several economic issues associated with celiac disease, including direct costs like healthcare services and medical management, as well as indirect costs such as reduced work…

Newly released data from Chugai Pharmaceuticals shows their drug candidate DONQ52 potently blocks gluten-specific t-cells and is ready for continued development. So, what does this mean for the celiac disease community?

The Celiac Disease Foundation is pleased to share important research and clinical trial news from Anokion, a biotechnology company evaluating a treatment for celiac disease. Using our iQualifyCeliac screening platform, the Foundation has supported patient enrollment through recruitment and eligibility screening for three of Anokion’s past and current trials: ACeD (Phase 1), ACeD-it (Phase 1b/2),…

Joining research studies and clinical trials is the only way to help scientists better understand this autoimmune disease and ultimately find a cure for celiac disease. This spring, I joined one of those important trials, funded by the Foundation, to help researchers with the development of a revolutionary new screening tool for celiac disease.

The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions.

DDW 2023 showcased some of the latest research and innovations in celiac disease. These included promising early results from four investigational medications currently being tested for the treatment of celiac disease, as well as CDF research conducted in partnership with Takeda and Adelphi Real World.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.